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Background
We are pleased to announce the launch of a new sec-
tion in the Journal for ImmunoTherapy of Cancer
(JITC), the Commentary/Editorials section edited by
Christian Capitini, MD of the University of Wisconsin.
With all of the changes occurring in the field of im-
munotherapy, we felt having a section that features
expert analysis and insight into the latest developments
would be useful to our readers.
So far in 2015, we have seen mounting excitement
around recent Food and Drug Administration (FDA)
approvals for new immunotherapeutics for cancer. In
March of this year, two monoclonal antibodies (mAbs)
were approved. The first approval was for the PD-1
pathway inhibitor nivolumab, which was approved for
metastatic non-small cell lung cancer (NSCLC). Nivo-
lumab was reviewed under the FDA’s priority review
program. The second approval involved the anti-GD2
therapy dinutuximab, which was approved for children
with high-risk neuroblastoma. Dinutuximab was granted
priority review and orphan product designation, and
became the second drug granted a rare pediatric disease
priority review voucher. It is only the third drug in history
to receive initial approval for the treatment of a pediatric
cancer.
In addition, we have seen promising reports from early
phase immunotherapy studies presented at the American
Association for Cancer Research (AACR) earlier this year.
In the ever-expanding field of mAbs for cancer, the first
phase III trial comparing the PD-1 inhibitor pembrolizu-
mab versus the CTLA4 inhibitor ipilimumab as first-line
therapy demonstrated that pembrolizumab was superior
in patients with metastatic melanoma according to all of
the study endpoints [1]. Moreover, recent analyses of
whole exome sequencing of NSCLC tumors treated with
pembrolizumab shows that higher mutational burden, a* Correspondence: ccapitini@pediatrics.wisc.edu
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and DNA repair pathway mutations improves efficacy [2].
Perhaps these results, combined with data showing that
presence of CD8+ T cells expressing PD-1 at the tumor
margin is associated with tumor regression [3], will
improve access to anti-PD-1 therapies for these patients,
especially in Europe where anti-PD-1 therapy is not
currently available as a first-line therapy. In a phase I trial
in patients with metastatic NSCLC, pembrolizumab was
found to be safe. Remarkably in a cohort of patients with
PD-L1+ tumors, the response rate was 45 % [4]. Beyond
melanoma and NSCLC, in a separate phase Ib trial,
pembrolizumab was reported to be safe for patients
with malignant pleural mesothelioma. Some clinical re-
sponses were reported.
MPDL3280A is a PD-L1 inhibitor that was previously
shown to induce response in metastatic bladder cancer
[5]. In a phase I clinical trial, MPDL3280A was reported
to be safe and showed some durable clinical activity in
patients with metastatic triple-negative breast cancer. In a
phase II, double-blind trial, the combination of ipilimu-
mab and nivolumab was reported to show better objective
clinical responses and progression-free survival than ipili-
mumab alone [6] And in a phase I clinical trial, the
anti-CD40 monoclonal antibody CP-870,893 was com-
bined safely with the CTLA4 inhibitor tremelimumab in
patients with metastatic melanoma, with non-overlapping
side effects reported as well as clinical responses. In a
phase I/IIa trial, a monoclonal T cell Receptor anti-CD3
scFv Fusion Protein IMCgp100 showed durable responses
in melanoma. In the field of adoptive cell therapy,
chimeric antigen receptor (CAR)-modified T cells against
mesothelin were well tolerated across patients with mul-
tiple tumor types. Importantly, no off-tumor, on-target
toxicity was reported.Conclusion
With the rapid expansion of mAb technologies such as
antibody-drug conjugates, immunotoxins, immunocyto-
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infiltrating lymphocytes (TILs), T cell receptor (TCR)-
transduced T cells, natural killer cells, and dendritic cell
vaccines, there will be lots to discuss in the coming
months (and years) ahead. We at JITC share your interest
and enthusiasm, and are prepared to keep you well in-
formed of the progress made in the immunotherapy of
cancer.
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